Featured News

New Phase 2 Clinical Trial: TEV-CeD2 Study

The ILLUMINATE-101 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

Many conventional brands actually have a hidden source of gluten in the ingredients list!

What if there was a way to help your immune system become more tolerant of gluten? That’s the potential of VTP-1000, an investigational immunotherapy being studied in the AVALON celiac disease clinical trial.

The Celiac Disease Foundation is committed to accelerating research aimed at finding potential treatments and cures for celiac disease beyond the gluten-free diet. In order to do this, we need…

A new international study published in the journal Gastroenterology sheds light on the extensive economic burden of celiac disease. In addition to the cost of gluten-free  foods, the authors address…

Newly released data from Chugai Pharmaceuticals shows their drug candidate DONQ52 potently blocks gluten-specific t-cells and is ready for continued development. So, what does this mean for the celiac disease community?

The Celiac Disease Foundation on May 22 awarded its first Celiac Disease Policy Leadership Award to U.S. Representative Betty McCollum (MN-04) for her distinguished service and advocacy on behalf of the celiac disease patient community. Among other initiatives, she established the bipartisan Congressional Celiac Disease Caucus, which has significantly increased federal recognition of celiac disease.

On May 20 the Disease Foundation hosted its third annual award reception at Digestive Disease Week in Washington, D.C. From prestigious global research prizes to inaugural student and policy leadership awards, the event spotlighted the extraordinary contributions of individuals dedicated to improving the lives of those affected by celiac disease.

The Celiac Disease Foundation is pleased to share important research and clinical trial news from Anokion, a biotechnology company evaluating a treatment for celiac disease. Using our iQualifyCeliac screening platform,…